Health care stocks were declining during Wednesday, with the NYSE Health Care Index falling nearly 0.6% while shares of health care companies in the S&P 500 were down almost 0.8% as a group. In company news, Omeros Corp (OMER) was surging Wednesday, with shares of the biopharmaceuticals company climbing to within 6 cents this morning of a 20-month high of $17.19 a share after the company earlier reported more positive data from the initial round of mid-stage testing for its OMS721 drug candidate to treat serious kidney disorders supports. It also said the new trial results support “rapid advancement” to Phase III testing.
The latest Phase II data for OMS721 in patients with stage 3b chronic kidney disease supplement data released earlier this year also showed a statistically significant improvement in protein levels in the patient’s urine. The Phase II trial is continuing, the company said, while it prepares to begin the final round of testing.